

Sugemalimab GEMSTONE-302

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Sugemalimab GEMSTONE-302

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
 Therapeutic Indication: Sugemalimab for the first-line treatment of metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy
 Experimental Arm: Sugemalimab + Platinum-based chemotherapy
 Control Arm: Placebo + platinum-containing chemotherapy

